pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
ALNYLAM PHARMACEUTICALS, INC. ($ALNY) · news · pharmadog
← back to ALNYLAM PHARMACEUTICALS, INC.
News mentioning $ALNY
9
stories
6d
ai3Bio, built from two biotechs, pursues a different path to an ‘immune reset’
biopharma dive
11d
ADARx scores upsized $446M IPO, while fellow RNA biotech City maps out Nasdaq plans
fiercebiotech
Aug 28, 26
‘Worse than expected’ Wainua data muddies water for TTR silencers
biospace
Aug 28, 26
STAT+: In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs
stat
Aug 27, 26
STAT+: Alnylam’s heart drug troubles take center stage at a cardiology conference
stat
Aug 11, 26
After tasting IPO success, Hemab’s CEO seeks ‘flavor of a multi-product coagulation company’
fiercebiotech
Jul 31, 26
Alnylam absorbs $10.8B blowback after cutting full-year guidance for TTR franchise
biospace
Jul 9, 26
AstraZeneca, Ionis drug fails big heart disease study in major setback
biopharma dive
Apr 28, 26
Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.
biopharma dive
